Zafgen Inc (NASDAQ:ZFGN)’s stock price rose 6.1% during trading on Wednesday . The company traded as high as $0.72 and last traded at $0.70, approximately 1,983,600 shares changed hands during mid-day trading. An increase of 443% from the average daily volume of 365,252 shares. The stock had previously closed at $0.66.

Several equities research analysts have weighed in on ZFGN shares. JMP Securities downgraded shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 5th. ValuEngine raised shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies reduced their target price on Zafgen from $6.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday, May 30th. Wedbush lowered Zafgen from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $6.00 to $0.78 in a research report on Friday, September 6th. Finally, Cowen reaffirmed a “hold” rating on shares of Zafgen in a research report on Thursday, May 30th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $6.05.

The business has a fifty day moving average of $0.86 and a 200-day moving average of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.98 and a current ratio of 6.98. The company has a market capitalization of $26.35 million, a P/E ratio of -0.37 and a beta of -0.52.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.06. Sell-side analysts anticipate that Zafgen Inc will post -1.15 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ZFGN. Gabelli Funds LLC bought a new stake in shares of Zafgen during the second quarter worth about $26,000. Northeast Financial Consultants Inc bought a new position in Zafgen in the 2nd quarter valued at about $28,000. Jefferies Group LLC acquired a new position in Zafgen during the 2nd quarter valued at about $32,000. SG Americas Securities LLC boosted its stake in Zafgen by 73.4% during the 2nd quarter. SG Americas Securities LLC now owns 27,032 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 11,447 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in Zafgen during the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 80.76% of the company’s stock.

Zafgen Company Profile (NASDAQ:ZFGN)

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

See Also: How does a security become overbought?

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.